AFP and metabolic dysfunction-associated steatotic liver disease: Obese patients with NAFLD usually do not present with specific symptoms besides a high BMI, metabolic syndrome manifestations, and normal or moderately elevated liver enzyme levels. These patients should be followed in clinical practice for the development of diabetes and HCC via US and alpha-fetoprotein every six months